神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/90006694

このアイテムのアクセス数:135件（2025-07-04 18:47 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
90006694 (fulltext) pdf 576 KB 48

メタデータ

ファイル出力

メタデータID
90006694
アクセス権
open access
出版タイプ
Version of Record
タイトル
Successful treatment of severe cholinergic urticaria with omalizumab: A case report
著者
Yamasaki, Aoi ; Oda, Yoshiko ; Tanizaki, Hideaki ; Otsuka, Toshihiro ; Fukunaga, Atsushi ; Nishigori, Chikako ; Moriwaki, Shinichi
著者名
Yamasaki, Aoi
著者名
Oda, Yoshiko
著者名
Tanizaki, Hideaki
著者名
Otsuka, Toshihiro
著者ID
A0799
研究者ID
1000010467649
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=894995f3b83db350520e17560c007669
著者名
Fukunaga, Atsushi
福永, 淳
フクナガ, アツシ
所属機関名
医学部附属病院
著者ID
A0395
研究者ID
1000050198454
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=e6f42019bd45236f520e17560c007669
著者名
Nishigori, Chikako
錦織, 千佳子
ニシゴリ, チカコ
所属機関名
医学研究科
著者名
Moriwaki, Shinichi
言語
English (英語)
収録物名
Journal of Cutaneous Immunology and Allergy
巻(号)
2(1)
ページ
31-34
出版者
Wiley
刊行日
2019-02
公開日
2020-01-23
抄録
Omalizumab, a humanized anti-IgE monoclonal antibody, has been approved in Japan for the treatment of antihistamine-resistant idiopathic chronic spontaneous urticaria. We herein report a 27-year-old Japanese woman suffering from a 2-year history of severe cholinergic urticaria (sweat allergy-type), which was unresponsive to various H2-antihistamines and other medication but was successfully treated with omalizumab. The patient showed rapid and marked reduction in her symptoms of urticaria after the first injection of omalizumab (300 mg). She has been receiving omalizumab treatment quaque 4 weeks (q4w) three times and subsequent q6w six times, followed by maintenance treatment q8w without any adverse reactions for a total of 68 weeks. Although further large-scale clinical investigation is needed, omalizumab may be a beneficial therapeutic remedy for patients with intractable, chronic inducible urticaria including cholinergic urticaria.
キーワード
cholinergic urticaria
chronic inducible urticaria
omalizumab
sweat allergy
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2019 The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy.
CC license
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
関連情報
DOI
https://doi.org/10.1002/cia2.12043